Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Poster Session A

Spondyloarthritis (SpA) including psoriatic arthritis (PsA)

Session: (0480–0482) Research Methodology – Interprofessional Poster

0482: Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis

Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Location: Poster Hall
On Demand In Person

    Abstract Poster Presenter(s)

  • JT

    Jingru Tian, MD (she/her/hers)

    Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
    Nanjing, Jiangsu, China

    Disclosure information not submitted.

Jingru Tian1, Shuntong Kang2, Dingyao Zhang3 and Qianjin Lu4, 1Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, 2Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Nanjing, China, 3Graduate Program in Biological and Biomedical Sciences, Yale University, New Haven, CT, 4Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China

Background/Purpose: Numerous indicators have been proposed to evaluate the efficacy for randomized clinical trials (RCTs) of psoriasis (Pso) and psoriatic arthritis (PsA), but the comparability and correlation remain unknown. To evaluate the preference and relative sensitivity of the mostly widely used indicators that report response rate, and to provide advice for the primary endpoint selection for Pso and PsA.

Methods: We conducted a systematic search including 3 databases and 4 registries to identify all pharmacological intervention-controlled RCTs of Pso. Bayesian hierarchical linear mixed model assessed the relative discriminations and provided a ranking of these indicators.

Results: Altogether 326 RCTs met our inclusion criteria, with 285 and 65 records on Pso and PsA, respectively. We found evidence of significant differences between indicators. Psoriasis Area and Severity Index (PASI) 50, PASI 75 and Investigator’s Global Assessment (IGA) 0,1 were powerful indicators to reveal the pharmacological efficacy in most RCTs of Pso(Figure 1). In contrast, PASI 125, Dermatology Life Quality Index (DIQI) 0,1 and Numerical Rating Scale (NRS) 4 were not preferred under different circumstances. Additionally, PASI 50, PASI 75 and PASI 90 seemed to be the most effective in nearly all types of pharmacological RCTs of PsA (Figure 2). However, due to their extremely sensitivity, American College of Rheumatology (ACR) 20 was also recommended to avoid exaggerating the therapeutic advantages of interventions. Instead, ACR 50, ACR 70 and Minimal Disease Activity (MDA) were the least sensitive, but they were supposed to be more cautious in evaluating disease changing. Indicator preference was slightly altered by disease severity, intervention type and administration method(Table 1).

Conclusion: The impressionable efficacy discrimination ability of indicators highlights the importance of flexibility and comprehensiveness when choosing primary outcome(s). As for trials that are only evaluated by indicators with extremely sensitivity, attention should be paid to the outcome interpretation to avoid the exaggeration of treatment efficacy.


Table 1. Recommendations for the selection of primary outcome of RCTs for psoriasis and psoriatic arthritis.


Figure 1. Preference of indicators reporting response rate in pharmacological intervention-controlled RCTs for psoriasis. (A) Bayesian hierarchical linear mixed model estimated effectiveness with 95% uncertainty intervals on indicators reporting response rate in pharmacological intervention-controlled RCTs for psoriasis. (B) The rank of indicators reporting response rate. The sooner an indicator reaches 1, the stronger ability to discriminate treatment efficacy.


Figure 2. Preference of indicators reporting response rate in pharmacological intervention-controlled RCTs for psoriatic arthritis. (A) Bayesian hierarchical linear mixed model estimated effectiveness with 95% uncertainty intervals on indicators reporting response rate in pharmacological intervention-controlled RCTs for psoriatic arthritis. (B) The rank of indicators reporting response rate. The sooner an indicator reaches 1, the stronger ability to discriminate treatment efficacy.


J. Tian: None; S. Kang: None; D. Zhang: None; Q. Lu: None.